High
0.449
Open
0.4348
VWAP
0.44
Vol
403.15K
Mkt Cap
5.30M
Low
0.430
Amount
178.06K
EV/EBITDA(TTM)
--
Total Shares
12.09M
EV
15.14M
EV/OCF(TTM)
--
P/S(TTM)
--
Impact Biomedical Inc. is a human healthcare company and is a wholly owned subsidiary of DSS, Inc. The Company, through the utilization of its intellectual property rights, or through investment in, or through acquisition of companies in the bio health and biomedical fields, focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The Company, through its subsidiary, Global BioLife, Inc., focuses on research in four main areas: the Linebacker project, which develops a universal therapeutic drug platform; a new sugar substitute called Laetose; a multi-use fragrance called 3F (Functional Fragrance Formulation), which is a mosquito fragrance product; and Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.
Show More
Valuation Metrics
The current forward P/E ratio for Impact Biomedical Inc (IBO.A) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Impact Biomedical Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2024Q4
N/A
Total Revenue
FY2024Q4
YoY :
-23.18%
-875.00K
Operating Profit
FY2024Q4
YoY :
+2051.70%
-27.13M
Net Income after Tax
FY2024Q4
YoY :
+2045.45%
-2.36
EPS - Diluted
FY2024Q4
YoY :
+190.07%
-1.26M
Free Cash Flow
FY2024Q4
N/A
Gross Profit Margin - %
FY2024Q4
N/A
FCF Margin - %
FY2024Q4
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
7.3M
USD
11
3-6
Months
17.1K
USD
4
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
310.0
USD
Months
3-6
2
4.0K
USD
Months
6-9
3
155.6K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
7.3M
USD
11
3-6
Months
17.1K
USD
4
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
310.0
USD
Months
3-6
2
4.0K
USD
Months
6-9
3
155.6K
USD
Months
0-12
0
0.0
USD
Months
IBO News & Events
Events Timeline
(ET)
2025-02-26
08:40:42
Impact BioMedical announces acquisition of Celios in $1.15M equity transaction
2025-02-26
08:36:20
DSS announces sale of Celios to Impact BioMedical
2024-11-19 (ET)
2024-11-19
07:09:05
Impact BioMedical CEO says 'well-positioned' to drive long-term value
Sign Up For More Events
Sign Up For More Events
News
Preview
4.5
04-04BenzingaDow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March
Preview
7.5
04-04BenzingaWhy Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Preview
5.0
03-25NASDAQ.COMInsider Sale: 10% owner at $IBO Sells 53,280 Shares
Sign Up For More News
People Also Watch
IIIN
Insteel Industries Inc
33.260
USD
+0.79%
GPRK
GeoPark Ltd
7.010
USD
+2.19%
SMBK
SmartFinancial Inc
30.120
USD
+0.10%
GAMB
Gambling.com Group Ltd
12.790
USD
+0.08%
MSBI
Midland States Bancorp Inc
16.560
USD
-0.30%
LZM
Lifezone Metals Ltd
3.470
USD
-4.93%
HIFS
Hingham Institution For Savings
253.530
USD
+1.28%
OUST
Ouster Inc
7.740
USD
-3.01%
FISI
Financial Institutions Inc
24.060
USD
+0.84%
MXCT
MaxCyte Inc
2.920
USD
+1.39%
FAQ
What is Impact Biomedical Inc (IBO) stock price today?
The current price of IBO is 0.4389 USD — it has increased 1.62 % in the last trading day.
What is Impact Biomedical Inc (IBO)'s business?
What is the price predicton of IBO Stock?
What is Impact Biomedical Inc (IBO)'s revenue for the last quarter?
What is Impact Biomedical Inc (IBO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Impact Biomedical Inc (IBO)'s fundamentals?
How many employees does Impact Biomedical Inc (IBO). have?